U.S., May 13 -- ClinicalTrials.gov registry received information related to the study (NCT07581951) titled 'A Phase 3 Study Evaluating the Safety and Efficacy of HSK31679 in Patients With MASH' on May 06.
Brief Summary: A phase 3, randomized, double-blind, placebo-controlled study evaluating the safety and tolerability of HSK31679 compared to placebo in patients with metabolic dysfunction-associated steatohepatitis (MASH) after 52 weeks of treatment.
Study Start Date: June 30
Study Type: INTERVENTIONAL
Condition:
MASH - Metabolic Dysfunction-Associated Steatohepatitis
NASH (Non-Alcoholic Steatohepatitis)
Intervention:
DRUG: HSK31679
tablet
DRUG: Placebo
Matching tablet
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Haisco Pharm...